AUTHORS
Saivaroon Gajagowni, MD, Denai Milton2, Frances Cervoni-Curet, MD3, Ricky Garcia4, Ligny Hunter5, Celina Ledesma6, Charles Martinez7, Gabriela Rondon, MD8, Yudith Carmazzi9, Kai Cao, MD, MS10, Jun Zou11, Gheath Alatrash, PhD12, Yosra M. Aljawai, MD MS13, Amin Alousi, MD14, Qaiser Bashir, MD15, George Chen, MD16, Chitra Hosing, MD17, Partow Kebriaei, MD18, Issa F. Khouri, MD19, Paul Lin, MD, PhD20, David Marin21, William Matsui, MD22, Rohtesh Mehta, MD, MPH23, Yago Nieto, MD, Ph.D24, Betul Oran, MD25, Uday Popat, MD, MBA26, Muzaffar Qazilbash, MD27, Jeremy Ramdial, MD28, Portia Smallbone, MBBS (Hons), FRACP, FRCPA29, Neeraj Saini, MD30, Samer A Srour, MB ChB, MS31, Richard Champlin32, Christopher R. Flowers Jr, MD, MS33, Elizabeth Shpall, MD34, Warren Fingrut, MD, MPH35
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
33 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
34 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
35 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Although PTCy-based GVHD prophylaxis (ppx) has extended allogeneic hematopoietic cell transplantation (HCT) access to patients (pts) from underserved populations, the extent to which disparities in allograft access persist is unknown.
Methods: We examined racial & socioeconomic (SES) disparities in graft source/characteristics & time to HCT in all adult 1st allograft recipients transplanted at our center 1/2018-12/2025 for acute myeloid leukemia (AML), a diagnosis for which HCT is urgent (since 1/2018, our center routinely used PTCy GVHD ppx for adult donor grafts). We defined: 1) low SES as the composite of neighborhood poverty [area deprivation index (ADI) ≥60%], Medicaid/Indigent insurance at time of HCT, &/or pt self-report of cost of living/medical expense insecurity; 2) HCT indication date as date of diagnosis if ELN 2017 int/high risk or high risk molecular mutations or secondary AML or extramedullary disease (n=833), else date of relapse (n=45); & 3) clinically significant delayed times to HCT as indication to HCT ≥180 days, indication to HCT physician consultation >90 days, & consult to HCT >120 days. Associations between delays to HCT & pt characteristics were evaluated using multivariable logistic regression models.
Results: Of 878 AML pts (median age 57 yrs, range 18-79; 89% received PTCy GVHD ppx), 588 (67%) were White/non-Hispanic & 290 (33%) non-White (61 Black, 109 Hispanic, 100 Asian, 20 other). Compared with White pts, on average, transplanted non-White pts were younger: median age 53 vs 60 yrs, p<.001.
Examining SES, 282 (32%) pts had low SES by ADI, 44 (5%) by insurance, & 39 (4%) by self-reported financial need. However, each measure classified different pts as low, with 322 (37%) pts having low SES by ≥1 measure but only 42 (5%) by ≥2 & only 1 by all 3. Compared with White pts, Black & Hispanic pts were more likely to have Medicaid/indigent insurance (15% vs 2%, p<.001) & low SES by ≥1 (54% vs 35%, p<.001) or ≥2 (13% vs 3%, p<.001) measures.
By donor type, 240 (27%) pts received HLA-identical related, 419 (48%) 8/8 unrelated donor (URD), 15 (2%) cord blood (CB), 150 (17%) haploidentical (haplo) & 54 (6%) 5-7/8 URD grafts (3 were 6/8 & 1 5/8). Compared with White pts, non-White pts received over twice the proportion of mismatched grafts (i.e., haplo/CB/5-7/8 URDs), 40% vs 18%, p<.0001. Over half (57%) of Black low SES pts received mismatched grafts.
Considering graft characteristics among recipients of each graft, compared with White pts, non-White pts received higher proportions of 8/8 URDs >35 yrs (28% vs 21%) & haplos >40 yrs (35% vs 21%). Use of 5-7/8 URDs increased over time [with 70% (38/54) of 5-7/8 URD recipients transplanted in the recent (1/2023-12/2025) period] & extended HCT access [i.e., 28 (52%) of 5-7/8 URDs were non-White & 25 (46%) had low SES by ≥1 measure]; however, a higher proportion of non-White pts had 5-7/8 URD grafts with greater mismatch (all four 5-6/8 URD recipients were non-White).
Median time from HCT indication to HCT was 152 days & 37% of pts faced delays to HCT ≥180 days. Compared with White pts, non-White pts had longer median times to HCT (160 vs 148 days) & a greater proportion with delays (43% vs 34%). Black & Hispanic pts had the longest median times to HCT (175 & 159 days) & the greatest proportions with delays (46% & 41%). Compared with pts without low SES measures, pts with ≥1 measure had longer median times to HCT (162 vs 147 days) & a higher proportion with delays (43% vs 34%).
In multivariable analysis, non-White pts [odds radio (95% CI) 1.55 (1.14, 2.12), p=.005], those with low SES [1.34 (1.01, 1.79), p=.045] & 8/8 URD recipients [1.53 (1.08, 2.17), p=.017] faced increased indication to HCT delays >180 days. Non-White pts faced delays across the pt journey [indication to consult >90 days: 1.45 (1.03, 2.05), p=.035; consult to HCT >120 days: 1.34 (0.98, 1.84), p=.06]. Recipients of 8/8 [2.05 (1.45, 2.90), p=.001] & 5-7/8 URDs [2.05 (1.11, 3.77), p=.043] faced increased delays from consult to HCT, the period when donor search & procurement occurred. Pts with Black race [2.08 (1.17, 3.70), p=.012] & low SES [1.81 (1.35, 2.42), p< .001] also faced increased consult to HCT delays. In subgroup analysis, non-White 8/8 & 5-7/8 URDs faced the greatest delays to HCT.
Conclusion: We demonstrate multiple levels of disparities in HCT access impacting underserved pts in the modern era, which will require significant, multifactorial interventions to address.
DISCLOSURES
Saivaroon Gajagowni, MD: No relevant conflicts of interest to declare.